ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1546

What Is the Impact of Smoking on the Risk of Rheumatoid Arthritis Progression: A Systematic Review of the Risk Factor Paradox

Sharan K. Rai1, Natalie McCormick2, Uyen Sa D.T. Nguyen3, Yuqing Zhang4, Jeffrey A. Sparks5, Elizabeth W. Karlson6 and Hyon K. Choi7, 1Experimental Medicine, University of British Columbia, Vancouver, BC, Canada, 2Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, 3Orthopedics and Physical Rehabilitation, University of Massachusetts Medical School, Worcester, MA, 4Clinical Epidemilogy and Training Unit, Boston University School of Medicine, Boston, MA, 5Division of Rheumatology, Immunology, and Allergy, Brigham & Women's Hospital, Boston, MA, 6Rheumatology, Brigham & Women's Hospital, Boston, MA, 7Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Epidemiologic methods, rheumatoid arthritis (RA) and tobacco use

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Rheumatoid Arthritis - Clinical Aspects Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatoid arthritis (RA) is a chronic
inflammatory disease that leads to progressive joint deformity, destruction,
and disability. While smoking is recognized as a strong environmental risk
factor for the development of RA, the relationship between smoking and the
progression of RA has often been reported to be inconsistent or paradoxical
(“the risk factor paradox”). To summarize the relevant data to date, we
conducted a systematic review of the literature on the impact of smoking on the
risk of RA progression.

Methods: We conducted a mapped search of MEDLINE
and EMBASE databases for articles published from database inception to June
2015. Additional articles were retrieved by a hand-search of relevant
bibliographies. Our search strategy used a combination of mapped subject
headings (i.e., MeSH and Emtree
terms) and keywords for unindexed concepts relating to the themes of RA
progression and smoking/tobacco use. Full-text
articles meeting the following criteria were included in the systematic review:
1) RA patient population; 2) outcome of a change in RA status (e.g., radiologic
progression, functional status, or disease severity); 3) original research
article; and 4) English language. Studies were excluded if they reported the
impact of smoking on the risk of incident RA. Non-human studies, reviews, and
case reports/series were additionally excluded.

Results: We identified 685 unique citations with
our search strategy. Of these, 28 studies met all inclusion criteria and were
included in the systematic review. The main outcomes
reported included radiographic progression (e.g., Larsen or Sharp/van der Heijde score) (n=14 studies), disease activity (e.g., DAS)
(n=13), treatment response (n=6), functional status and disability (e.g., HAQ) (n=7),
achievement of remission (n=2), and total joint replacement (n=1). Overall,
smoking did not have a significant impact on RA outcomes and progression, and
in some studies (n=4) smoking actually conferred a protective impact (see Table). Only two of 14 studies on
radiographic progression reported a hazardous effect, and the impact of smoking
on functional status was non-significant in all studies identified.
Additionally, there was no significant association between smoking status and
achievement of remission.

Conclusion: While smoking is a
well-established risk factor for incident RA, findings from the majority of
studies identified in this systematic review suggest that it does not confer
the same impact on disease progression
. Although
biological explanations for these counterintuitive results may exist, an
enticing methodologic explanation is a type of selection bias known as index
event bias. Appropriate methods to correct for this bias
should be explored to determine the true impact of smoking on the risk of RA
progression.

Table. Summary of Reported Associations between Smoking and RA Progression

Outcome

Protective or Null Association

Hazardous Association

Radiologic progression (n=14)

12

 2*

Disease activity (n=13)

11

2

Treatment response (n=6)

5

1

Functional status/disability (n=7)

7

0

Remission (n=2)

2

0

Total joint replacement (n=1)

1

0

*One was based on a cross-sectional analysis of a cohort study

           



Disclosure: S. K. Rai, None; N. McCormick, None; U. S. D. T. Nguyen, None; Y. Zhang, None; J. A. Sparks, None; E. W. Karlson, None; H. K. Choi, None.

To cite this abstract in AMA style:

Rai SK, McCormick N, Nguyen USDT, Zhang Y, Sparks JA, Karlson EW, Choi HK. What Is the Impact of Smoking on the Risk of Rheumatoid Arthritis Progression: A Systematic Review of the Risk Factor Paradox [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/what-is-the-impact-of-smoking-on-the-risk-of-rheumatoid-arthritis-progression-a-systematic-review-of-the-risk-factor-paradox/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/what-is-the-impact-of-smoking-on-the-risk-of-rheumatoid-arthritis-progression-a-systematic-review-of-the-risk-factor-paradox/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology